logo

For the Inventor, By the Inventor

Ardsley, NY, United States of America

Osi Pharmaceuticals, Inc.


USPTO Granted Patents = 118



Trademarks = 2

Forward Citations = 940

Loading Chart...
Loading Chart...

186 inventors (with patents filed for the assignee):

goldMedal Andrew Philip Crew (28 out of 72 patents)

silverMedal Arlindo Lucas Castelhano (25 out of 44 patents)

bronzeMedal Mark Joseph Mulvihill (24 out of 25 patents)

4.  An-Hu Li (21 out of 26 patents)

5.  Arno G Steinig (15 out of 15 patents)

6.  Douglas S Werner (14 out of 20 patents)

7.  Bryan McKibben (14 out of 15 patents)

8.  David James Witter (13 out of 49 patents)

9.  Bijoy Panicker (13 out of 28 patents)

10.  Hanqing Dong (12 out of 52 patents)

11.  Jing Wang (12 out of 53 patents)

12.  Radoslaw Laufer (11 out of 30 patents)

13.  Xin Chen (11 out of 17 patents)

14.  Lee Daniel Arnold (11 out of 40 patents)

15.  Ayako Honda (10 out of 16 patents)


Core Competencies:
Pulse Dosing Regimen
EMT Gene Signatures
Isothiazole Derivatives
Macrocyclic Kinase Inhibitors
Amino Pyrimidine Compounds
Fused Bicyclic Inhibitors
Biological Markers
Combined Cancer Therapy
EGFR Kinase Inhibitors
mTOR Inhibitors
Integrin Antagonists
Dipeptidyl Peptidase IV

118 patents:

1. 11833149 - Pulse dosing regimen and methods of treatment (2023-12-05),
2. 11253520 - Pulse dosing regimen and methods of treatment (2022-02-22),
3. 10583142 - Pulse dosing regimen and methods of treatment (2020-03-10),
4. 9896730 - Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment (2018-02-20),
5. 9371298 - Processes for the preparation of isothiazole derivatives (2016-06-21),
6. 9351974 - Substituted pteridinones for the treatment of cancer (2016-05-31),
7. 9244058 - Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors (2016-01-26),
8. 9133224 - Macrocyclic kinase inhibitors (2015-09-15),
9. 9096624 - Amino pyrimidine anticancer compounds (2015-08-04),
10. 8796455 - Fused bicyclic mTOR inhibitors (2014-08-05),
11. 8735405 - 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors (2014-05-27),
12. 8653268 - 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors (2014-02-18),
13. 8642834 - Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation (2014-02-04),
14. 8592448 - Substituted pyrrolo[2,3-b]-pyridines and -pyrazines (2013-11-26),
15. 8586546 - Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors (2013-11-19),
OSI Pharmaceuticals, Inc. is a biotechnology company that specializes in the discovery, development, and commercialization of novel therapeutics for the treatment of cancer. With a focus on targeted therapies, OSI Pharmaceuticals is dedicated to transforming the lives of patients by advancing innovative treatment options. For more information, please visit their official website.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

118 Patents

#1 in Ardsley, NY

#183 in New York

#3,138 in US

#6,536 in the World

...
Ardsley, NY, United States of America

Osi Pharmaceuticals, Inc.

Forward Citations = 940

186 inventors:

goldMedal Andrew Philip Crew (28 out of 72 patents)

silverMedal Arlindo Lucas Castelhano (25 out of 44 patents)

bronzeMedal Mark Joseph Mulvihill (24 out of 25 patents)

4.  An-Hu Li (21 out of 26 patents)

5.  Arno G Steinig (15 out of 15 patents)

Please report any incorrect information to support@idiyas.com
Loading…